Director, Imaging Biomarkers

Responsibilities

• Define and execute the imaging biomarker strategy aligned with clinical and translational objectives
• Lead the development, validation, and qualification of imaging biomarkers for disease characterization and patient stratification
• Collaborate with cross-functional teams including clinical development, biostatistics, and regulatory affairs
• Evaluate and implement cutting-edge imaging technologies such as MRI, PET, CT, ultrasound, and optical imaging
• Partner with external imaging CROs, academic institutions, and technology vendors
• Oversee vendor selection and budget management for imaging-related activities
• Manage imaging biomarker operations in clinical studies including protocol development and data quality assurance

Requirements

• Ph.D., M.D., or equivalent in Biomedical Engineering, Medical Physics, Radiology, or related scientific disciplines
• 10+ years of experience in imaging biomarker development within pharma, biotech, or academic research
• Deep scientific expertise in at least one major imaging modality, preferably MRI
• Proven track record in applying imaging biomarkers in clinical trials and regulatory submissions
• Expertise in quantitative imaging methodologies and image analysis software
• Strong leadership and project management skills
• Excellent communication and presentation skills

Preferred Qualifications

• Familiarity with AI/ML approaches for image analysis
• Understanding of digital biomarkers using wearables or sensors
• Knowledge of disease-specific imaging biomarkers in neurology, cardiology, or neuromuscular fields

About the Company

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.